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and 54 increased signiﬁcantly (4.550.86 vs 5.020.80; 2.580.69 vs
3.290.75, P<0.05), the same with the level of LDL-C in patients aged
between 55 and 64 (2.730.63 vs 3.210.89, P <0.05).
CONCLUSIONS Dyslipidemia has remained further deterioration, and
taken on atherogenic lipid proﬁle, it is especially obviously for male or
middle-aged patients with AMI. Powerful measures must be taken to
control dyslipidemia, targeted strategy should focuses on these pop-
ulation.GW26-e0710
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OBJECTIVES To evaluate the association between very low density
lipoprotein cholesterol (VLDL-C) and cholesterol absorption and
synthesis markers, for the exploration of the effective therapy to
reduce VLDL-C levels.
METHODS Total 363 statin-naïve patients with high risk of coronary
heart disease were recruited consecutively from two hospitals in
Shanxi and Henan provinces between October 2008 and June 2009. A
standard questionnaire and physical examination were conducted at
baseline. Atorvastatin was administered to patients at a dose of 20 mg
per day for 4 weeks. Venous blood samples after an overnight fast
were collected before and after treatment for laboratory measure-
ments, including VLDL-C and cholesterol absorption and synthesis
markers.
RESULTS (1) Of 363 patients, 318 were followed through this study,
and among them, 283 patients with mean age of 55.439.01 years
old were remained ﬁnally after excluding patients who were lost to
follow-up or with incomplete information. The median level of
baseline VLDL-C was 1.06 (0.65, 1.86) mmol/L. The median level of
baseline cholesterol absorption marker (Campesterol) and choles-
terol synthesis marker (Lathosterol) was 0.60 (0.78,0.94) mg/dl and
1.35 (0.83,2.11) mg/dl, respectively. (2) Partial correlation analysis
and multiple regression showed the baseline level of VLDL-C was
positively correlated with Campesterol (r¼0.153,b¼0.367, P<0.05)
but not with Lathosterol. Furthermore, in different cholesterol ab-
sorption and synthesis patterns, baseline VLDL-C level signiﬁcantly
increased with tertile of the baseline level of Campesterol in the
qualitative analysis. (3) A mean reduction in VLDL-C levels was
37.97% after 4 weeks atorvastatin treatment. The reduction of
VLDL-C level was positively correlated with the reduction in Cam-
pesterol (r¼0.331, P<0.001). And in the qualitative analyses, the
reduction in VLDL-C levels signiﬁcantly increased with the tertile of
Campesterol reduction (P for trend¼0.032). But this trend was not
observed for the association between the changes of VLDL-C level
and Lathosterol.
CONCLUSIONS The level of VLDL-C was closely related to cholesterol
absorption marker, and further studies are needed to validate the
hypothesis that whether the inhibitor of cholesterol absorption (Eze-
timibe) could bring about more effective VLDL-C lowering.GW26-e2268
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OBJECTIVES Familial hypercholesterolemia (FH) is a common and
serious dominant genetic disease, which characteristic by tendon
xanthoma, severely elevated LDL cholesterol (LDL-C) and premature
coronary heart disease. The main pathogenic gene is low density li-
poprotein receptor (LDLR) gene, which can explain 75% FH patients.
However, less data were reported in China. This study aim to system
review the LDLR mutations in China.
METHODS With a computerized literature index of Pubmed,
Embase, Wangfang (Chinese) and Chinese National Knowledge
Infrastructure (CNKI, Chinese), Chinese Biological and Medicaldatabase (CBM, Chinese), the public date were limited to December
2014. The Medical Subject Headings terms and following key words
were used: “familial hypercholesterolemia”, “Chinese”, “China”,
“Hong Kong”, “Taiwan”. Studies only included LDLR mutations
were included.
RESULTS A total of 59 studies were included in our review. There
are 340 probands included 129 LDLR mutations were reported. The
distribution of mutations showed most mutations were located in
exon 4 andbout 60% (77/129) mutations were missense mutations.
In addition, we found 28 novel mutations which were not recorded
in the LDLR databases. In silico analysis, most of mutations were
pathogenic, except two variants were identiﬁed as non-pathogenic:
N494S (c.1544A>G, p. Asn515Ser) and S533L (c.1661C>T, p. Ser554-
Leu). In addition, the three main mutations in China were C308Y
(c.986G>A, p.Cys329Tyr), H562Y (c.1747C>T, p.His583Tyr), and
A606T (c.1879G>A, p.Ala627Thr) and all of them had functional
analysis.
CONCLUSIONS The prevalence of heterozygous FH is found in
approximately 1/200 - 1/500, there are nearly 6 million patients in
China. This system review collect LDLR mutations in China, may
provide Chinese information to the international FH database.
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OBJECTIVES To study correlation between cholesterol synthesis with
absorption and reactivity to statin of high-risk coronary heart disease
(CHD) people with different cholesterol synthesis and absorption
degrees.
METHODS 159 subjects with high-risk CHD were enrolled, and 20mg
atorvastatin per day were taken for four weeks. Blood lipids and
markers of cholesterol synthesis and absorption were determined
respectively before and after treatment. Squalene/TC (Squalenea) and
Sitoserlo/TC (Squalenea) were analyzed, which represents the levels
of cholesterol synthesis and absorption, respectively.
RESULTS ① In the low-absorption group, the high synthesis people
accounted for 41%, the low for 12.8%; In the high absorption
group, the high synthesis people only accounted for 7.5%, the low
is as high as 35%, with signiﬁcantly difference (p ¼ 0.001). With the
increase of synthesis, the number of subjects with high absorption
decreases. Accordingly, with the increase of absorption, the number
of subjects with high synthesis decreases as well, trend test p ¼
0.0001. ②; After statin treatment, no subject with synthesis greatly
reduced in low synthesis group, but as high as 75% in high syn-
thesis group, statistical difference signiﬁcant (p ¼ 0.000). With the
increase of synthesis, the number of synthesis reduced increases,
trend test p ¼ 0.000. ③After treatment, the synthesis reduction is
51.3% in low absorption group, but only 22.5% in high absorption
group, with signiﬁcantly difference (p ¼ 0.035). With increasing of
absorption, the number of synthesis reduced decreases, trend test
p ¼ 0.033.
CONCLUSIONS The negative feedback regulation mechanism be-
tween cholesterol synthesis and absorption exists in the Chinese high-
risk CHD population. The higher cholesterol synthesis degree in
baseline, the better reactivity to statin, but it shows the opposite
tendency for cholesterol absorption.GW26-e2276
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OBJECTIVES To explore the relationship between fasting serum level
of b2-microglobulin (b2-M) and arteriosclerosis in primary aldoste-
ronism (PA).
